CAS 1038915-60-4: Niraparib
Description:Niraparib is a small molecule inhibitor primarily used in the treatment of certain types of cancer, particularly ovarian cancer. It functions as a poly(ADP-ribose) polymerase (PARP) inhibitor, which interferes with the DNA repair mechanisms in cancer cells, leading to cell death. Niraparib is characterized by its ability to selectively target cancer cells with deficiencies in homologous recombination repair, such as those with BRCA mutations. The compound is typically administered orally and has a favorable pharmacokinetic profile, allowing for once-daily dosing. Its chemical structure includes a pyridine ring and a nitrogen-containing heterocycle, contributing to its potency and selectivity. Niraparib has been shown to improve progression-free survival in patients with recurrent ovarian cancer, making it a significant therapeutic option in oncology. As with many cancer therapies, it may have side effects, including fatigue, nausea, and hematological toxicities, which require monitoring during treatment. Overall, Niraparib represents a targeted approach in cancer therapy, exemplifying the advancements in precision medicine.
Formula:C19H20N4O
InChI:InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1
InChI key:InChIKey=PCHKPVIQAHNQLW-CQSZACIVSA-N
SMILES:O=C(N)C1=CC=CC2=CN(N=C21)C3=CC=C(C=C3)C4CNCCC4
- Synonyms:
- (S)-2-(4-(Piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide
- 2-[4-(3S)-3-Piperidinylphenyl]-2H-indazole-7-carboxamide
- 2-[4-[(3S)-Piperidin-3-yl]phenyl]indazole-7-carboxamide
- 2H-Indazole-7-carboxamide 2-[4-(3S)-3-piperidinylphenyl]-